Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-trace').style.display = (document.getElementById('cakeErr67f724b618d2a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f724b618d2a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-code').style.display = (document.getElementById('cakeErr67f724b618d2a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-context').style.display = (document.getElementById('cakeErr67f724b618d2a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f724b618d2a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f724b618d2a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31482,
		&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679555,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31482,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31482,
	&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679555,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31482
$metaTitle = &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;
$metaKeywords = &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;
$metaDesc = &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /></em><br />Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /><br />MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br /><br />&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br /><br />A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br /><br />Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br /><br />For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-trace').style.display = (document.getElementById('cakeErr67f724b618d2a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f724b618d2a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-code').style.display = (document.getElementById('cakeErr67f724b618d2a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-context').style.display = (document.getElementById('cakeErr67f724b618d2a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f724b618d2a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f724b618d2a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31482,
		&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679555,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31482,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31482,
	&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679555,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31482
$metaTitle = &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;
$metaKeywords = &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;
$metaDesc = &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /></em><br />Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /><br />MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br /><br />&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br /><br />A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br /><br />Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br /><br />For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-trace').style.display = (document.getElementById('cakeErr67f724b618d2a-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f724b618d2a-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-code').style.display = (document.getElementById('cakeErr67f724b618d2a-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f724b618d2a-context').style.display = (document.getElementById('cakeErr67f724b618d2a-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f724b618d2a-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f724b618d2a-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31482,
		&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679555,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31482,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31482,
	&#039;title&#039; =&gt; &#039;If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;
&lt;br /&gt;
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;
&lt;br /&gt;
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;
&lt;br /&gt;
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;
&lt;br /&gt;
For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679555,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31482
$metaTitle = &#039;LATEST NEWS UPDATES | If India signs RCEP, it will not be the &amp;#039;pharmacy of the world&amp;#039;: MSF -Vidya Krishnan&#039;
$metaKeywords = &#039;TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs&#039;
$metaDesc = &#039;
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;Humanitarian aid organisation M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF) has warned India that the country will not remain &amp;lsquo;pharmacy of the developing world&amp;rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.&lt;br /&gt;&lt;br /&gt;MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&amp;rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &amp;lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&amp;rdquo; said Leena Menghaney, South Asia Head of MSF&amp;rsquo;s Access Campaign.&lt;br /&gt;&lt;br /&gt;A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &amp;ldquo;alarming&amp;rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&amp;rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &amp;lsquo;Data Exclusivity&amp;rsquo; and &amp;lsquo;Patent Term Extensions&amp;rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.&lt;br /&gt;&lt;br /&gt;Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &amp;ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&amp;rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &amp;ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&amp;rdquo; Mr. Basheer added.&lt;br /&gt;&lt;br /&gt;For India, agreeing to data exclusivity will mean amending the Drugs &amp;amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /></em><br />Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /><br />MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br /><br />&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br /><br />A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br /><br />Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br /><br />For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 31482,
		'title' => 'If India signs RCEP, it will not be the 'pharmacy of the world': MSF -Vidya Krishnan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br />
</em><br />
Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br />
<br />
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br />
<br />
&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br />
<br />
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br />
<br />
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br />
<br />
For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
</div>',
		'credit_writer' => 'The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4679555,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 31482,
	'metaTitle' => 'LATEST NEWS UPDATES | If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan',
	'metaKeywords' => 'TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs',
	'metaDesc' => '
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the...',
	'disp' => '<div align="justify">-The Hindu<br /><br /><em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /></em><br />Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /><br />MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br /><br />&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br /><br />A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br /><br />Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br /><br />For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 31482,
	'title' => 'If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br />
</em><br />
Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br />
<br />
MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br />
<br />
&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br />
<br />
A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br />
<br />
Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br />
<br />
For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.
</div>',
	'credit_writer' => 'The Hindu, 14 June, 2016, http://www.thehindu.com/sci-tech/health/mdecins-sans-frontires-on-indias-role-in-the-rcep-meet/article8728609.ece?w=alauto',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'if-india-signs-rcep-it-will-not-be-the-039pharmacy-of-the-world039-msf-vidya-krishnan-4679555',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4679555,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 31482
$metaTitle = 'LATEST NEWS UPDATES | If India signs RCEP, it will not be the &#039;pharmacy of the world&#039;: MSF -Vidya Krishnan'
$metaKeywords = 'TRIPS,generic drugs,generic medicine,generic medicines,patents,Intellectual Property Rights,Médecins Sans Frontières (MSF),IPRs'
$metaDesc = '
-The Hindu

The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.

Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the...'
$disp = '<div align="justify">-The Hindu<br /><br /><em>The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /></em><br />Humanitarian aid organisation M&eacute;decins Sans Fronti&egrave;res (MSF) has warned India that the country will not remain &lsquo;pharmacy of the developing world&rsquo; if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland.<br /><br />MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market.<br /><br />&ldquo;Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India&rsquo;s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that &lsquo;India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,&rdquo; said Leena Menghaney, South Asia Head of MSF&rsquo;s Access Campaign.<br /><br />A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several &ldquo;alarming&rdquo; proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation&rsquo;s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for &lsquo;Data Exclusivity&rsquo; and &lsquo;Patent Term Extensions&rsquo;- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement.<br /><br />Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. &ldquo;This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,&rdquo; explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. &ldquo;A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,&rdquo; Mr. Basheer added.<br /><br />For India, agreeing to data exclusivity will mean amending the Drugs &amp; Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

If India signs RCEP, it will not be the 'pharmacy of the world': MSF -Vidya Krishnan

-The Hindu The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland. Humanitarian aid organisation Médecins Sans Frontières (MSF) has warned India that the country will not remain ‘pharmacy of the developing world’ if the proposals in the Regional Comprehensive Economic Partnership agreement (RCEP) are adopted. The RCEP is a regional trade agreement being negotiated between the 10 ASEAN countries currently in Auckland. MSF Access Campaign along with other civil society organisations are pushing for the removal of harmful intellectual property provisions that could potentially increase drug costs by creating new monopolies and delaying the entry of affordable generics in the market. “Unless negotiators remove harmful provisions from RCEP, this trade deal is set to follow the dangerous path of the US-led Trans-Pacific Partnership agreement, which is recognised globally as the worst trade deal ever for access to medicines. We appeal to India’s IP negotiators in particular, to stand by the promises made last week by Health Minister J.P. Nadda at the UN High Level Meeting on HIV/AIDS that ‘India is committed to maintaining TRIPS flexibilities to ensure access to affordable medicines,” said Leena Menghaney, South Asia Head of MSF’s Access Campaign. A leaked copy of the intellectual property text being discussed at RCEP negotiations shows that Japan and South Korea have made several “alarming” proposals to include intellectual property rules that go beyond what international trade rules - agreed under World Trade Organisation’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) require. Two of the most worrying proposals in the trade deal is the demand for ‘Data Exclusivity’ and ‘Patent Term Extensions’- both intellectual property obligations that Least Developing Countries (LDCs) were completely exempted from until 2033 according to the WTO TRIPS agreement. Data Exclusivity is a form of legal monopoly protection for a drug, over and above the patent protections. “This is given expressly to compensate for the investment made during clinical trials. It implied that regulators cannot approve a similar drug with similar data for the next 5 years, delaying the entre of generic, affordable versions,” explains Prof Shamnad Basheer, an expert in IP Law and a visiting professor at the National Law School of India University in Bengaluru. Patent terms extensions are given to compensate the company for delays in processing the patent applications. “A company gets a 20 year patent monopoly on a drug from the date that the application was filed. Sometimes processing these applications takes time and the companies get only 13 years instead of 20. A patent term extension will give another 5 year monopoly to the innovator company, again delay the entry of generic drugs in the market,” Mr. Basheer added. For India, agreeing to data exclusivity will mean amending the Drugs & Cosmetic Act (FDA law) so that the Indian Drug Regulatory Authority (DRA) is prohibited from registering a more affordable version of a medicine as long as the exclusivity lasts over the clinical trial data.